🔗 Permalink

Inventor profile of:

Florian Holsboer

City:

Munich

Country:

Germany

Published Applications:

Last publication date:

2021-07-08

Top Assignees for applications by Florian Holsboer

The entities that hold a legal rights for patent applications filed by inventor Holsboer Florian:

Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. 3 Munich, Germany
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. 1 Munich, Germany
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 1 Munchen, Germany
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFT E.V. 1 Munich, Germany
Max-Planck-Gesellschaft zur Förderung der Wissenshaften e.V. 1 Munich, Germany
Max-Planck-Gesellschft Zur Foerderung Der Wissenschaften e.V. 1 Muenchen, Germany
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN e.V. 1 Muenchen, Germany
MAX PLANCK SOCIETY 1 Munich, Germany
HMNC Holding GmbH 1 Munich, Germany
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFT E.V. 1 MUNICH, Germany
B.R.A.H.M.S GMBH 1 HENNIGSDORF, Germany

Recent patent applications by Holsboer Florian

Florian Holsboer from Munich, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2021-07-08

US20210207199A1

Chemistry; metallurgy

Genetic Predictors of a Response to Treatment with CRHR1 Antagonists

#2 | 2021-05-06

US20210130899A1

Chemistry; metallurgy

Method of Treatment Using Genetic Predictors of a Response to Treatment with CRHR1 Antagonists

#3 | 2019-12-05

US20190365708A1

Human necessities

Vreceptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level

#4 | 2019-06-27

US20190194752A1

Chemistry; metallurgy

Method for predicting a treatment response to a CRHR1 antagonist and/or a Vantagonist in a patient with depressive and/or anxiety symptoms

#5 | 2018-12-13

US20180355430A1

Chemistry; metallurgy

Genetic Predictors of a Response to Treatment with CRHR1 Antagonists

#6 | 2018-05-03

US20180119221A1

Chemistry; metallurgy

Method of Treatment Using Genetic Predictors of a Response to Treatment with CRHR1 Antagonists

#7 | 2016-09-29

US20160279204A1

Human necessities

PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT BY NASAL ADMINISTRATION OF PATIENTS SUFFERING FROM ANXIETY AND SLEEP DISORDERS

#8 | 2016-06-02

US20160153043A1

Chemistry; metallurgy

Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms

#9 | 2014-09-04

US20140249090A1

Human necessities

PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT BY NASAL ADMINISTRATION OF PATIENTS SUFFERING FROM ANXIETY AND SLEEP DISORDERS

#10 | 2012-04-19

US20120094855A1

Chemistry; metallurgy

MEANS AND METHODS FOR DIAGNOSING PREDISPOSITION FOR TREATMENT EMERGENT SUICIDAL IDEATION (TESI)

#11 | 2012-02-16

US20120039812A1

Chemistry; metallurgy

Genes associated with posttraumatic-stress disorder (PTSD)

#12 | 2010-08-26

US20100216653A1

Chemistry; metallurgy

USE OF POLYMORPHISMS IN THE TMEM132D GENE IN THE PREDICTION AND TREATMENT OF ANXIETY DISORDERS

#13 | 2008-03-13

US20080064609A1

Chemistry; metallurgy

Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments

InventorID:

896604 ⎘